A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 25 Oct 2017 The study has been Discontinued in Denmark. (End date: 2017-09-20).
- 20 Jul 2017 The study has been completed in Spain.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History